“Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis”

Patients who are diagnosed with Relapsing Multiple Sclerosis may qualify for a new study titled “Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis”.

The study’s objective is to assess the safety and effectiveness of the study medication in reducing the number of new active brain lesions reported with Magnetic Resonance Imaging (MRI) with patients with Relapsing MS.

Inclusion Criteria :

▪  The participant must be aged between 18 to 55 years of age and have been diagnosed with Relapsing Multiple Sclerosis.

▪  The participant must have at least 1 documented relapse within the previous year, ≥2 documented relapses within the previous 2 years, or ≥1 active Gd- enhancing brain lesion on an MRI scan in the past 6 months and prior to screening.

Exclusion Criteria :

▪  The participant has been diagnosed with Primary-Progressive MS (PPMS) or with non-relapsing Secondary-Progressive MS (SPMS)

▪  The participant has an EDSS score >5.5 at the first screening visit

▪  The participant has had a relapse in the 30 days prior to randomization

Study medication:

The study   medication   belongs   to   a   class   of   medicines   called   Bruton's   tyrosine kinase inhibitors (BTKi), which can reduce the activity of the BTK enzyme in cells from the body's immune system.

BTK is a molecule involved   in   the development of B cells and microglia, which can be involved in the disease process of MS. By reducing the B cells and microglia activation, this may decrease   inflammation   in   the brain.

The proposed mechanism of action for the study medication is to prevent  the  formation  of new brain lesions in MS.

The study medication will be administered orally (by mouth) as a tablet.

To learn more about the study, please visit https://clinicaltrials.gov/ct2/show/NCT03889639?term=dri15928&rank=1

Article Provided by:  #MSViewsandNews

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::